The Competition and Markets Authority (CMA) has decided to close its investigation into the alleged anti-competitive agreements and concerted practices in relation to generic pharmaceutical products.
The watchdog announced its decision is based on administrative priority grounds. The authority further stated that it has not reached a view on whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to the parties under investigation.
“This decision does not amount to a statement or finding as to whether the party to the investigation has infringed competition law, nor should any inference be made to that effect,” the authority announced in the closure statement.
The CMA launched the investigation on October 10, 2017, and expanded the scope in July this year, amid the backdrop of rising generics prices that affected community pharmacies hard.
Featured News
FTC Sues to Block Tempur Sealy’s $4.3 Billion Acquisition of Mattress Firm
Oct 24, 2024 by
CPI
Mexican Watchdog Proposes Fintech Reforms to Boost Financial Inclusion
Oct 24, 2024 by
CPI
AMA and ISMS File Antitrust Lawsuit Against MultiPlan Over Alleged Price-Fixing Scheme
Oct 24, 2024 by
CPI
Biden Administration Announces New AI Strategy to Boost National Security
Oct 24, 2024 by
CPI
Google Agrees to Provide AI-Related Documents in Monopoly Case
Oct 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Chevron
Oct 24, 2024 by
CPI
A Quartet of Decisions That Cripple Agencies
Oct 24, 2024 by
Richard J. Pierce
Goodbye, Chevron: Rediscovering the Virtues of an Independent Judiciary
Oct 24, 2024 by
Alexander Volokh
A New Era of Deference: From Chevron to Loper Bright
Oct 24, 2024 by
Daniel E. Walters
Loper Bright and Antitrust: Limited Impact on Enforcement, but a Clear Constraint on FTC Rulemaking
Oct 24, 2024 by
David Kully, Lynn Calkins & Kenneth Racowski